Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Videos

Narendranath Epperla, MD, MS
Videos
Promising Prognostic Value of Diagnosis to Treatment Interval Among Patients With Newly Diagnosed Mantle Cell Lymphoma
08/17/2023

Featuring Narendranath Epperla, MD, MS

Featuring Narendranath Epperla, MD, M...
Narendranath Epperla, MD, MS, shares findings assessing the potential significance of DTI for predicting outcomes for patients with newly diagnosed MCL.
Narendranath Epperla, MD, MS, shares findings assessing the potential significance of DTI for predicting outcomes for patients with newly diagnosed MCL.
Narendranath Epperla, MD, MS,...
08/17/2023
Oncology
Susan M. O'Brien, MD
Videos
Optimal Frontline Treatment Regimens for Patients With Chronic Lymphocytic Leukemia
08/16/2023

Featuring Susan M. O'Brien, MD

Featuring Susan M. O'Brien, MD ...
At the 2023 EHA meeting in Frankfurt, Germany, Susan M. O'Brien, MD, provided insights into the latest frontline therapeutic options for patients with chronic lymphocytic leukemia.
At the 2023 EHA meeting in Frankfurt, Germany, Susan M. O'Brien, MD, provided insights into the latest frontline therapeutic options for patients with chronic lymphocytic leukemia.
At the 2023 EHA meeting in...
08/16/2023
Oncology
Gerald Prager, MD, Medical University of Vienna
Videos
Trifluridine/Tipiracil Plus Bevacizumab For Refractory Metastatic Colorectal Cancer
08/11/2023

Featuring Gerald Prager, MD

Featuring Gerald Prager, MD
At the 2023 World Congress on Gastrointestinal Cancers, Gerald Prager, MD, presents data on a trial evaluating trifluridine/tipiracil plus bevacizumab for patients with refractory metastatic colorectal cancer.
At the 2023 World Congress on Gastrointestinal Cancers, Gerald Prager, MD, presents data on a trial evaluating trifluridine/tipiracil plus bevacizumab for patients with refractory metastatic colorectal cancer.
At the 2023 World Congress on...
08/11/2023
Oncology

Advertisement

Anna Wagner, MD, University of Lausanne
Videos
Addition of Trastuzumab to Perioperative Chemotherapy Improved Response Rates Among Patients with HER2-Positive Gastric or Gastroesophageal Junction Cancer
08/11/2023

Featuring Anna Wagner, MD

Featuring Anna Wagner, MD
At the 2023 World Congress on Gastrointestinal Cancers, Anna Wagner, MD, discusses the addition of trastuzumab to perioperative chemotherapy for patients with HER2-positive gastric or gastroesophageal junction cancer.
At the 2023 World Congress on Gastrointestinal Cancers, Anna Wagner, MD, discusses the addition of trastuzumab to perioperative chemotherapy for patients with HER2-positive gastric or gastroesophageal junction cancer.
At the 2023 World Congress on...
08/11/2023
Oncology
Zev Wainberg, MD, University of California - Los Angeles
Videos
NALIRIFOX Regimen As First-Line Therapy for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
08/10/2023

Featuring Zev Wainberg, MD

Featuring Zev Wainberg, MD
At the 2023 World Congress on Gastrointestinal Cancers, Zev Wainberg, MD, presents data from the NAPOLI 3 study, evaluating NALIRIFOX in the first-line setting for patients with metastatic pancreatic ductal adenocarcinoma.
At the 2023 World Congress on Gastrointestinal Cancers, Zev Wainberg, MD, presents data from the NAPOLI 3 study, evaluating NALIRIFOX in the first-line setting for patients with metastatic pancreatic ductal adenocarcinoma.
At the 2023 World Congress on...
08/10/2023
Oncology
Akihito Kawazoe, MD, National Cancer Center East - Japan
Videos
Lenvatinib Plus Pembrolizumab Did Not Significantly Improve Survival Among Patients with Metastatic Colorectal Cancer
08/10/2023

Featuring Akihito Kawazoe, MD

Featuring Akihito Kawazoe, MD
At the 2023 World Congress on Gastrointestinal Cancers, Akihito Kawazoe, MD, shared results from the phase 3 LEAP-017 trial, evaluating lenvatinib plus pembrolizumab among previously treated patients with metastatic colorectal cancer.
At the 2023 World Congress on Gastrointestinal Cancers, Akihito Kawazoe, MD, shared results from the phase 3 LEAP-017 trial, evaluating lenvatinib plus pembrolizumab among previously treated patients with metastatic colorectal cancer.
At the 2023 World Congress on...
08/10/2023
Oncology

Advertisement

Andrea Bullock, MD, Harvard Medical School
Videos
Botensilimab-Balstilimab Showed Durable Responses for Metastatic Microsatellite Stable Colorectal Cancer
08/10/2023

Featuring Andrea Bullock, MD

Featuring Andrea Bullock, MD
At the 2023 World Congress on Gastrointestinal Cancers, Andrea Bullock, MD, discussed the expanded phase 1 trial of bostensilimab plus balstilimab for heavily pretreated, metastatic microsatellite stable colorectal cancer.
At the 2023 World Congress on Gastrointestinal Cancers, Andrea Bullock, MD, discussed the expanded phase 1 trial of bostensilimab plus balstilimab for heavily pretreated, metastatic microsatellite stable colorectal cancer.
At the 2023 World Congress on...
08/10/2023
Oncology
Michael Pishvaian, MD, PhD, Johns Hopkins University
Videos
Intra-Arterial Gemcitabine Showed Promise for Locally Advanced Pancreatic Cancer
08/10/2023

Featuring Michael Pishvaian, MD, PhD

Featuring Michael Pishvaian, MD, PhD ...
At the 2023 World Congress on Gastrointestinal Cancers, Michael Pishvaian, MD, PhD, shared data from the first interim analysis of a phase 3 study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
At the 2023 World Congress on Gastrointestinal Cancers, Michael Pishvaian, MD, PhD, shared data from the first interim analysis of a phase 3 study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
At the 2023 World Congress on...
08/10/2023
Oncology
Leony Antoun, MD, Gustave Roussy Cancer Campus
Videos
Effect of Molecular Profiling on Survival Among Patients With Biliary Tract Cancers
08/09/2023

Featuring Leony Antoun, MD

Featuring Leony Antoun, MD
At the 2023 World Congress on Gastrointestinal Cancers, Leony Antoun, MD, discusses the impact of molecular profiling on survival among patients with advanced biliary tract cancers.
At the 2023 World Congress on Gastrointestinal Cancers, Leony Antoun, MD, discusses the impact of molecular profiling on survival among patients with advanced biliary tract cancers.
At the 2023 World Congress on...
08/09/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use